vs
LIVEPERSON INC（LPSN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
LIVEPERSON INC的季度营收约是REGENXBIO Inc.的2.0倍（$59.3M vs $30.3M），LIVEPERSON INC净利率更高（-77.8% vs -221.3%，领先143.6%），REGENXBIO Inc.同比增速更快（43.0% vs -19.0%），LIVEPERSON INC自由现金流更多（$-12.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -16.6%）
LivePerson是一家全球性科技企业，专注于开发对话式商务与人工智能软件，相关产品与解决方案能够帮助企业搭建智能对话体系，优化客户沟通体验，助力企业实现数字化商务运营转型。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LPSN vs RGNX — 直观对比
营收规模更大
LPSN
是对方的2.0倍
$30.3M
营收增速更快
RGNX
高出62.0%
-19.0%
净利率更高
LPSN
高出143.6%
-221.3%
自由现金流更多
LPSN
多$40.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-16.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.3M | $30.3M |
| 净利润 | $-46.1M | $-67.1M |
| 毛利率 | 73.2% | — |
| 营业利润率 | -68.7% | -190.0% |
| 净利率 | -77.8% | -221.3% |
| 营收同比 | -19.0% | 43.0% |
| 净利润同比 | 58.9% | -31.2% |
| 每股收益（稀释后） | $-9.22 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LPSNRGNX
| Q4 25 | $59.3M | $30.3M | ||
| Q3 25 | $60.2M | $29.7M | ||
| Q2 25 | $59.6M | $21.4M | ||
| Q1 25 | $64.7M | $89.0M | ||
| Q4 24 | $73.2M | $21.2M | ||
| Q3 24 | $74.2M | $24.2M | ||
| Q2 24 | $79.9M | $22.3M | ||
| Q1 24 | $85.1M | $15.6M |
净利润LPSNRGNX
| Q4 25 | $-46.1M | $-67.1M | ||
| Q3 25 | $8.7M | $-61.9M | ||
| Q2 25 | $-15.7M | $-70.9M | ||
| Q1 25 | $-14.1M | $6.1M | ||
| Q4 24 | $-112.1M | $-51.2M | ||
| Q3 24 | $-28.3M | $-59.6M | ||
| Q2 24 | $41.8M | $-53.0M | ||
| Q1 24 | $-35.6M | $-63.3M |
毛利率LPSNRGNX
| Q4 25 | 73.2% | — | ||
| Q3 25 | 71.4% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.8% | — | ||
| Q4 24 | 77.4% | 70.2% | ||
| Q3 24 | 73.1% | 48.8% | ||
| Q2 24 | 79.4% | 52.5% | ||
| Q1 24 | 71.3% | 72.6% |
营业利润率LPSNRGNX
| Q4 25 | -68.7% | -190.0% | ||
| Q3 25 | -24.2% | -176.3% | ||
| Q2 25 | -10.8% | -296.3% | ||
| Q1 25 | -26.2% | 13.6% | ||
| Q4 24 | -138.0% | -242.1% | ||
| Q3 24 | -21.6% | -256.6% | ||
| Q2 24 | -37.3% | -251.3% | ||
| Q1 24 | -42.7% | -408.8% |
净利率LPSNRGNX
| Q4 25 | -77.8% | -221.3% | ||
| Q3 25 | 14.5% | -208.3% | ||
| Q2 25 | -26.4% | -331.8% | ||
| Q1 25 | -21.8% | 6.8% | ||
| Q4 24 | -153.2% | -241.3% | ||
| Q3 24 | -38.1% | -246.3% | ||
| Q2 24 | 52.3% | -237.7% | ||
| Q1 24 | -41.8% | -405.4% |
每股收益（稀释后）LPSNRGNX
| Q4 25 | $-9.22 | $-1.30 | ||
| Q3 25 | $-2.76 | $-1.20 | ||
| Q2 25 | $-0.17 | $-1.38 | ||
| Q1 25 | $-0.24 | $0.12 | ||
| Q4 24 | $-17.23 | $-0.99 | ||
| Q3 24 | $-4.74 | $-1.17 | ||
| Q2 24 | $-0.33 | $-1.05 | ||
| Q1 24 | $-0.40 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $95.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-44.5M | $102.7M |
| 总资产 | $454.7M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LPSNRGNX
| Q4 25 | $95.0M | $230.1M | ||
| Q3 25 | $106.7M | $274.2M | ||
| Q2 25 | $162.0M | $323.3M | ||
| Q1 25 | $176.3M | $267.9M | ||
| Q4 24 | $183.2M | $234.7M | ||
| Q3 24 | $142.1M | $255.5M | ||
| Q2 24 | $146.0M | $290.4M | ||
| Q1 24 | $127.1M | $338.7M |
总债务LPSNRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $512.1M | — |
股东权益LPSNRGNX
| Q4 25 | $-44.5M | $102.7M | ||
| Q3 25 | $-22.1M | $161.5M | ||
| Q2 25 | $-82.4M | $213.7M | ||
| Q1 25 | $-74.9M | $274.2M | ||
| Q4 24 | $-67.3M | $259.7M | ||
| Q3 24 | $45.9M | $301.4M | ||
| Q2 24 | $66.6M | $348.3M | ||
| Q1 24 | $19.2M | $390.7M |
总资产LPSNRGNX
| Q4 25 | $454.7M | $453.0M | ||
| Q3 25 | $511.4M | $525.2M | ||
| Q2 25 | $604.2M | $581.0M | ||
| Q1 25 | $596.2M | $490.9M | ||
| Q4 24 | $607.8M | $466.0M | ||
| Q3 24 | $692.0M | $519.1M | ||
| Q2 24 | $703.8M | $569.4M | ||
| Q1 24 | $724.7M | $629.2M |
负债/权益比LPSNRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 26.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-12.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | -20.2% | -174.0% |
| 资本支出强度资本支出/营收 | 3.9% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-42.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LPSNRGNX
| Q4 25 | $-9.7M | $-52.3M | ||
| Q3 25 | $-6.0M | $-56.0M | ||
| Q2 25 | $-11.7M | $-49.3M | ||
| Q1 25 | $-3.1M | $33.6M | ||
| Q4 24 | $-3.1M | $-31.6M | ||
| Q3 24 | $4.8M | $-40.5M | ||
| Q2 24 | $-17.9M | $-45.5M | ||
| Q1 24 | $1.1M | $-55.5M |
自由现金流LPSNRGNX
| Q4 25 | $-12.0M | $-52.8M | ||
| Q3 25 | $-8.9M | $-56.5M | ||
| Q2 25 | $-14.8M | $-49.7M | ||
| Q1 25 | $-6.9M | $32.6M | ||
| Q4 24 | $-6.8M | $-32.7M | ||
| Q3 24 | $-230.0K | $-40.9M | ||
| Q2 24 | $-22.9M | $-46.0M | ||
| Q1 24 | $-10.4M | $-56.0M |
自由现金流率LPSNRGNX
| Q4 25 | -20.2% | -174.0% | ||
| Q3 25 | -14.8% | -189.9% | ||
| Q2 25 | -24.9% | -232.8% | ||
| Q1 25 | -10.6% | 36.6% | ||
| Q4 24 | -9.2% | -154.2% | ||
| Q3 24 | -0.3% | -168.9% | ||
| Q2 24 | -28.7% | -206.2% | ||
| Q1 24 | -12.2% | -358.5% |
资本支出强度LPSNRGNX
| Q4 25 | 3.9% | 1.7% | ||
| Q3 25 | 4.8% | 1.7% | ||
| Q2 25 | 5.3% | 1.8% | ||
| Q1 25 | 5.8% | 1.2% | ||
| Q4 24 | 5.0% | 5.1% | ||
| Q3 24 | 6.8% | 1.3% | ||
| Q2 24 | 6.2% | 2.1% | ||
| Q1 24 | 13.5% | 3.6% |
现金转化率LPSNRGNX
| Q4 25 | — | — | ||
| Q3 25 | -0.69× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.43× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LPSN
| Hosted Services Business | $51.0M | 86% |
| Professional Services | $8.3M | 14% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
